• Publications
  • Influence
SAFE biopsy: A validated method for large‐scale staging of liver fibrosis in chronic hepatitis C
SAFE biopsy is a rational and validated method for staging liver fibrosis in hepatitis C with a marked reduction in the need for liver biopsy and is an attractive tool for large‐scale screening of HCV carriers. Expand
The impact of liver disease aetiology and the stages of hepatic fibrosis on the performance of non‐invasive fibrosis biomarkers: an international study of 2411 cases
Aliment Pharmacol Ther 2011; 34: 1202–1216
Inflammation and Repair in Viral Hepatitis C
The role of cytokines in the adaptive immune response against the HCV infection, the progression of fibrosis, and the risk factors of co-morbidity with alcohol and human immunodeficiency virus in HCV-infected individuals are discussed. Expand
Transjugular intrahepatic portosystemic shunt.
The prevention and therapy of upper digestive hemorrhage due to rupture of esophageal varices in patients with liver cirrhosis and a transjugular intrahepatic portosystemic shunt (TIPS) is achieved by a new method which, without requiring general anesthesia, creates a shunt between a portal vein branch and the inferior vena cava. Expand
Alcoholic and non-alcoholic steatohepatitis.
The present review includes pre-clinical, translational and clinical research that characterize alcoholic liver disease (ALD) and non-alcoholic steatohepatitis (NASH) and examines the role of genetics in the development of ASH and NASH. Expand
Prevalence of steatosis and insulin resistance in patients with chronic hepatitis B compared with chronic hepatitis C and non-alcoholic fatty liver disease.
In CHB steatosis is related to host and not viral factors, and is not associated with the severity of fibrosis, and HOMA-IR was an independent predictor of FibroTest in CHC. Expand
Adding pegylated interferon to entecavir for hepatitis B e antigen–positive chronic hepatitis B: A multicenter randomized trial (ARES study)
24 weeks of Peg‐IFN add‐on therapy led to a higher proportion of HBeAg response, compared to ETV monotherapy, and resulted in more viral decline and appeared to prevent relapse after stopping ETV, suggesting Peg‐ifN add-on therapy may facilitate the discontinuation of nucleos(t)ide analogs. Expand
A cross-sectional epidemiological study of HBV, HCV, HDV and HEV prevalence in the SubCarpathian and South-Eastern regions of Romania.
In the South and South-Eastern Romania the seroprevalence of viral hepatitis infections is intermediate, similar to other Romanian regions or the Balkans. Expand
The role of cytokines in non-alcoholic steatohepatitis. A review.
A better understanding of how cytokines, hormones, neurotransmitters, and other soluble and cell associated factors regulate the phenotypes of different types of liver cells should help to develop rationale treatments for NASH and other disorders in the metabolic syndrome. Expand
New therapeutical indications of ursodeoxycholic acid.
The beneficial effects of ursodeoxycholic acid (UDCA) in primary biliary cirrhosis have provided the first firm evidence that bile acids may in some way be related to injury in man. Expand